Locations:
Search IconSearch
August 28, 2017/Digestive/Case Study

Treatment of “Unresectable” Bilobar Liver Metastasis Using a 2-Stage Approach and HAI: A Case Study

Experienced team, innovative treatment

17-DDI-3877-Quintini-CQD-Hero

By Cristiano Quintini, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Presentation

A 42-year-old female was referred to our institution with large right colon cancer and synchronous bilobar liver metastasis (see presenting CT scan of the liver above). A particular challenge was presented by the lesion encasing the three hepatic veins of the liver (see arrows).

Treatment

The patient received three months of perioperative chemotherapy and was scheduled (three months after the initial presentation) for a two-stage hepatectomy and a combined resection of the primary right colon tumor.

The first surgery included a right hemicolectomy with resection of all the left-sided liver lesions. The surgery was uneventful. On postoperative day 6, the patient underwent a right portal vein embolization with the intent to induce hypotrophy of the right hemi liver and the hypertrophy of the left hemi liver. This approach is used to decrease the risks of postresection liver failure.

Six weeks after the first operation, the patient underwent a right hepatectomy. Given her young age and the extent of the disease, the decision was made to place to also place a hepatic artery infusion (HAI) pump to further decrease her likelihood of recurrence. HAI locoregional treatment is an innovative approach that improves survival after liver resection for metastatic colon cancer. This treatment option is only delivered in selected centers around the world.

The remnant left liver lobe with a catheter inside the gastro-duodenal artery for HAI treatment.

The remnant left liver lobe with a catheter inside the gastro-duodenal artery for HAI treatment.

Outcome

One year after the initial presentation, the patient is free of tumor (see scan below) and receiving routine follow-up scans.

Advertisement

CT scan showing the patient free of tumor.

CT scan showing the patient free of tumor.

Advertisement

Related Articles

Patient holding injectable
March 26, 2026/Digestive/Research

New Analysis Examines Long-Term Outcomes of GLP-1 Therapies in Type 1 Diabetes

Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies

melanoma
February 13, 2026/Digestive/Case Study

Case Study: An Immunotherapy-First Approach for a 79-Year-Old With Stage IIB Melanoma

Benefits of neoadjuvant immunotherapy reflect emerging standard of care

Dr. Laique leading shared medical appointment

MASH-Cirrhosis and Obesity: Transforming Care with Shared Medical Appointments

Multidisciplinary framework ensures safe weight loss, prevents sarcopenia and enhances adherence

Pharmacist reaching for medication
October 31, 2025/Digestive/Research

Sulfamethoxazole/Trimethoprim Outperforms Ciprofloxacin for Preventing SBP Recurrence in Cirrhosis

Study reveals key differences between antibiotics, but treatment decisions should still consider patient factors

Physician using model of colon
October 30, 2025/Digestive/Research

Understanding Colonic Oligopolyposis of Unknown Etiology: Insights from a Cleveland Clinic Study

Key points highlight the critical role of surveillance, as well as opportunities for further advancement in genetic counseling

Woman sleeping
October 29, 2025/Digestive/Research

Sleep Positioning Device Improves Lung Function in Transplant Recipients with GERD

Potentially cost-effective addition to standard GERD management in post-transplant patients

Patient holding injectable
October 27, 2025/Digestive/Research

Tirzepatide Linked to Better Heart Outcomes Than Semaglutide in MASLD, Obesity and Diabetes

Findings could help clinicians make more informed decisions about medication recommendations

Anthony de Buck, MD, MSc
October 17, 2025/Digestive/News

Cleveland Clinic Names Anthony de Buck, MD, as New Section Head of IBD

Insights from Dr. de Buck on his background, colorectal surgery and the future of IBD care

Ad